Appendix B
Biographical Sketches of Committee Members, Presenters, and Moderators
Mostafa Abdelaal is a molybdenum-99 production operator at the Radioisotope Production Factory at the Egyptian Atomic Energy Authority (EAEA). He worked at EAEA in 2007 and then obtained a master’s degree in 2012 and a doctorate in radiochemistry in 2016. Beside molybdenum-99 and iodine-131 production, he works as a researcher in the field of radioisotopes production and labeling.
Gavin Ball serves as group executive for operations at NTP Radioisotopes where he is responsible for safe, efficient, and sustainable production operations of the company’s radioisotope production plants in South Africa. He has been involved in the nuclear industry for 30 years and has more than 20 years’ experience in isotope production. During this period he has specifically been involved in key leadership roles in the highly enriched uranium (HEU) to low-enriched uranium (LEU) conversion projects.
Bruce Begg is an executive manager within Nuclear Business at the Australian Nuclear Science and Technology Organisation (ANSTO), with responsibility for identifying and developing strategic commercial opportunities for ANSTO. He has more than 20 years’ experience with ANSTO’s synroc technology, from initially leading its technical development to now overseeing its commercialization.
Carmen Bigles is president and CEO of Coquí RadioPharmaceuticals Corp. (Coquí Pharma), a company founded in 2009 with the goal of establishing a medical radioisotope production facility in the United States. Prior to founding Coquí Pharma, Bigles co-founded and served as chief financial officer of the Caribbean Radiation Oncology Center in Puerto Rico. Bigles was born in San Juan, Puerto Rico, and received her education in Florida and Puerto Rico. In 1997, she earned a bachelor’s degree in mathematics from Interamerican University in San Juan and subsequently master’s degrees in architecture and suburban and town planning from the University of Miami in 2000.
Roy Brown is currently the vice president of Government Affairs & Strategic Alliances for Curium. His principal responsibility is engaging with state and federal legislators, regulatory agencies, and trade associations to educate and advocate on behalf of Curium. He is also engaged in the long-term strategy for radionuclide supply. He has more than 30 years of experience in the nuclear medicine industry. He holds a B.S. in radiation biophysics from the University of Kansas and an M.A. in business administration from Webster University.
Ken Buckley has a bachelor of science degree in physics from McMaster University. He has more than 30 years’ experience in the production and use of medical radioisotopes, particularly in the field of positron emission tomography (PET). His experience includes accelerator operation and maintenance, targetry development, automated radiochemistry development, and PET camera characterization. Since 2011 he has been the project manager for the TRIUMF-led collaboration of five institutions establishing cyclotron-based direct production of Tc-99m. In 2015 the collaboration won the Natural Sciences and Engineering Research Council Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering.
Alexander Bychkov is the representative of Rosatom in Vienna and has the post of senior counsellor of the Russian Permanent Mission for International Organizations in Vienna. He is out-of-staff adviser to the director general of Rosatom and visiting professor at the National Nuclear Research University MEPhI (Moscow Engineering Physics Institute). Before that he was a deputy director general of the International Atomic Energy Agency (IAEA) until February 2015 and a director general of the Research Institute of Atomic Reactors in Dimitrovgrad, Russia, until 2011. He graduated with a degree in chemistry from Moscow State University in 1982 and received his doctorate in 1998. His main areas of activity cover nuclear fuel-cycle subjects, including nuclear fuel, fast reactors and high-level waste, radionuclide technologies, and research reactor applications. Bychkov is a co-author of more than 160 scientific works.
Jack L. Coffey serves as a consultant with Enigma Biomedical Group and Cerveau Technologies Inc., focusing on radiopharmaceutical development with primary emphasis on supplier and manufacturing site qualification, U.S. Food and Drug Administration compliance, and manufacturing process improvements. His experience at Cardinal Health Nuclear Pharmacy Services (2003-2012) and Syncor International Corporation (1984-2003) has included regulatory compliance auditing, quality and regulatory affairs management, as well as an officer of a publicly held corporation. As a scientist at Oak Ridge Associated Universities (1974-1984) he conducted radiopharmaceutical research focused specifically on determining radiation doses to patients and members of the public from radioactive materials. Coffey chaired the Council on Radionuclides and Radiopharmaceuticals (CORAR) from 2011 to 2012. He received a B.S. in chemistry and biology from the University of the Cumberlands and an M.S. in radiation biology from the University of Tennessee.
Pablo Cristini, born in 1958, is an Argentine radiochemist, who graduated from the University of Buenos Aires in 1985. In 1979, he joined the Comisión Nacional de Energía Atómica (CNEA) of Argentina, participating in the Fission Mo-99 Production Project. In 1991 he became the head of the CNEA fission Mo-99 production plant and since 2005 has been manager of radioisotope production, responsible for the conversion of Mo-99 production from HEU to LEU. He is author or co-author of more than 30 scientific papers and publications. He had technical responsibility for transference of technology of Mo-99 production with LEU to the Australian Nuclear Science and Technology Organisation, the Egyptian Atomic Energy Authority, the Nuclear Research Center of Draria, Algeria, and the Board of Radiation and Isotope Technology (BRIT) in India.
Brendan Cuddy joined the European Medicines Agency as a scientific administrator in October 2002. Cuddy is currently head of the Manufacturing and Quality Compliance Service and is chairman of the Good Manufacturing and Distribution Practice Inspectors Working Group (GMDP IWG). The service plays a key role in collaborating and communicating with international partners on setting and recognizing GMP standards, making better use of inspectional resources, and exchanging information on the availability of already authorized medicines. Cuddy obtained his degree in chemistry from the University of Dublin, Trinity College in Ireland. He holds a master’s degree from the National University of Ireland in quality and operations management and a postgraduate diploma in pharmaceutical manufacturing technology from University of Dublin, Trinity College, which satisfies the educational requirements for Qualified Person.
Michael Druce is Nuclear Business’s chief technology officer and manager of Client Office activities for the new ANM Plant. He provides technical support for Nuclear Business Projects and Operations. Druce has extensive
experience in the development and manufacture of radioisotopes for both medical and industrial applications. He provides technical advice on ANSTO projects and consulting services to other organizations. He is the technical director for the new ANM Mo-99 Plant and is responsible for preparing the plant for operations. He holds bachelor of applied science (chemistry) and master of business administration degrees. He graduated from the Australian School of Nuclear Technology and the Australian Institute of Company Directors. He has more than 30 years of experience with both reactor- and cyclotron-based radioisotopes. He is based at ANSTO’s Lucas Heights campus.
Jin Du is the chief technology officer at China Isotope & Radiation Corporation. Dr. Du received his B.S. (1986) in chemical engineering from the Wuhan Institute of Chemical Technology and Ph.D. (2001) in chemistry from the University of Jyvaskyla, Finland. He started as a research fellow in medical radioisotopes and radiopharmaceuticals fields at China Institute of Atomic Energy in 1986, and then moved to the Japan Atomic Energy Research Institute (1996), MAP Medical Technologies, Oy, Finland (1997), and Peking University Health Research Center (2002). He accepted a senior research position in the China Isotope & Radiation Corporation (2006) and then was promoted to chief technology officer in 2016 where his main responsibility is research and development of new medical radioisotopes and radiopharmaceuticals.
Charles Ferguson has been the president of the Federation of American Scientists (FAS) since January 1, 2010. From February 1998 to August 2000, Ferguson worked for FAS on nuclear proliferation and arms control issues as a senior research analyst. Previously, from 2002 to 2004, Ferguson had been with the Monterey Institute’s Center for Nonproliferation Studies (CNS) as its scientist-in-residence. He also has consulted with the Oak Ridge National Laboratory, Sandia National Laboratories, and the National Nuclear Security Administration. From 2000 to 2002, he served as a physical scientist in the Office of the Senior Coordinator for Nuclear Safety at the U.S. Department of State, where he helped develop U.S. government policies on nuclear safety and security issues. After graduating with distinction from the U.S. Naval Academy, he served as an officer on a fleet ballistic missile submarine and studied nuclear engineering at the Naval Nuclear Power School. Ferguson received his undergraduate degree in physics from the U.S. Naval Academy in Annapolis, Maryland, and his M.A. and Ph.D. degrees, also in physics, from Boston University in Massachusetts. Dr. Ferguson is the incoming director of the National Academies’ Nuclear and Radiation Studies Board.
Ira Goldman is director, Strategic Supply and Government Relations, Lantheus Medical Imaging (LMI). He is co-chair of the Isotope Supply Committee, Council on Radioisotopes and Radiopharmaceuticals (CORAR), and vice chair of the Reactor and Isotopes Working Group, Association of Imaging Producers and Equipment Suppliers (European Industrial Association for Nuclear Medicine and Molecular Imaging). Goldman is responsible for developing, implementing, and monitoring corporate strategy and actions for acquisition of a globally diversified and reliable supply of Mo-99, including strategic planning for Mo-99 and Tc-99m, analysis of global Mo-99 supply options; establishing and expanding relationships with global suppliers for a reliable and high-quality supply of Mo-99 and materials; and managing projects for technical evaluation of various Mo-99 and Tc-99m production technologies. He is also responsible for legislative and governmental relations and assists with new business development for medical radioisotopes.
Margarida Goulart has a pharmaceutical sciences degree, a medical degree, and a Ph.D. in genetic toxicology, and worked as a researcher and university professor for several years, in toxicology of organic and inorganic compounds and radioactive elements, in Portugal (National Institute of Nuclear Technology) and the United States (Brown University, University of North Carolina). She is currently a permanent staff member of the European Commission (EC) as a research programme officer in the Joint Research Centre’s (JRC’s) Euratom Coordination Unit, responsible mainly for the coordination of nuclear security and nuclear science application activities, including cooperation between the EC and the International Atomic Energy Agency (Seibersdorf and Monaco labs) and the JRC contribution to EC actions toward security of the supply of medical radioisotopes.
Yann Guinard is the managing director of CERCA™ at AREVA NP. He joined AREVA in 2009, and was previously the vice president in charge of strategy of AREVA’s Fuel Business Unit. Prior to that, he held several management positions in various industries, with a focus on aerospace. He holds master’s degrees in public affairs and business administration.
Carolyn Haass is the chief operating officer of Northwest Medical Isotopes. She has more than 30 years of experience in multidisciplinary complex nuclear, chemical, hazardous, and mixed waste engineering, procurement, construction, and project management projects in both the government and private industry. She was a regulator with the U.S. Department of Energy for more than 10 years and has extensive communication experience in the nuclear and environmental industry including day-to-day interface with regulators, safety boards, Congress, stakeholders, tribal nations, public, media, community leaders, and decision makers. Haass earned a bachelor of science degree in chemistry and metallurgical engineering from Colorado School of Mines.
James Harvey holds a Ph.D. in nuclear chemistry. He has 44 years of experience in both federal and private positions in nuclear research, development, and commercial applications of radioactive materials. He has held principal investigator roles on a number of grants and cooperative agreements and grants with various federal agencies. He has extensive experience working within and with various Department of Energy programs including environmental cleanup and radioisotope production applications. He has served as the chief science officer of NorthStar Medical Technologies, LLC for the past 12 years.
Hedvig Hricak is chair of the Department of Radiology at Memorial Sloan-Kettering Cancer Center. As a member of the Institute of Medicine/National Academy of Medicine, her contributions have included chairing the Committee on the State of the Science of Nuclear Medicine (2006-2007) and the Committee on Research Directions in Human Biological Effects of Low-Level Ionizing Radiation (2012), and serving as vice chair of the Committee on Tracking Radiation Doses from Medical Diagnostic Procedures (2012). She served on the Nuclear and Radiation Studies Board of the National Academy of Sciences from 2008 to 2014.
Stepan Kalmykov is the head scientist at the Laboratory of Radioecological and Radiation Problems of the Institute of Physical Chemistry of Moscow State University and the head of the Division of Nuclear and Radiation Medicine of the National Research Center Kurchatov Institute. His research focuses on actinide speciation, colloid-facilitated radionuclide migration, surface complexation modeling, determination of low-level activities, and nuclear medicine and radiopharmaceutical chemistry. He is a member of the Scientific Council on Radiochemistry (a partnership between the Russian Academy of Sciences and Rosatom), the International Nuclear Chemistry Society, the Scientific Secretary of the National Committee of Russian Chemists, and the American Chemical Society.
Kinam Kim is a senior researcher at Korea Atomic Energy Research Institute (KAERI). He received his Ph.D. in material science and engineering from Hanyang University, Korea, in 2013. He began his career at KAERI in 2013 as a researcher working on producing and studying research reactor fuels. Since April 2017, he has worked as a project manager developing atomized powder-based high-density LEU dispersion targets.
Matthew Lish is a graduate of the University of North Carolina at Chapel Hill with a bachelor of science degree in chemistry, and the University of Tennessee at Knoxville with a doctorate in nuclear engineering, concentrating in system dynamics, instrumentation, and control. Lish currently works as a reactor dynamicist at Flibe Energy in Hunstville, Alabama, where he is developing a closed-fuel-cycle thorium nuclear reactor known as the liquid fluoride thorium reactor, or “lifter” (LFTR). His areas of interest include reactor dynamics and simulation, inorganic separations chemistry, chemical process engineering, reactor dynamics, and radiation-hardened electronics for signal processing.
Hermen van der Lugt is director of PALLAS. PALLAS is responsible for all required preparations for the construction of the PALLAS reactor in Petten, Netherlands. The PALLAS reactor will take over the current role of
the HFR reactor in the supply chain of isotopes. Activities include requirements specification, reactor design, and nuclear and conventional licensing. The PALLAS organization develops a business case for PALLAS that enables private investors to fund the construction and operation.
Kennedy Mang’era is chief operating officer (COO) at the Canadian Isotope Innovations Corp (CIIC), based in Saskatoon, Canada. Mang’era was previously director of the radiopharmacy for Winnipeg Health, a technical/scientific leader for the Prairie Isotope Production Enterprise, and head of the Radiopharmaceuticals Research Group. In these roles, he led critical research initiatives into isotope production technologies prior to joining the commercialization private company, CIIC, as a founder and COO. Mang’era is an adjunct professor at the University of Winnipeg, and is past president of the Canadian Association of Radiopharmaceutical Scientists.
Anupam Mathur is a scientist working in the Radiopharmaceuticals Program of the Board of Radiation and Isotope Technology (BRIT), Department of Atomic Energy, India. He joined the department after completing 1 year of training in radiochemistry from Bhabha Atomic Research Centre, India. Currently, he is involved in bulk production of a few regular ready-to-use injectable radiopharmaceuticals based on radioisotopes such as 131I/32P/153Sm/177Lu supplied by BRIT for clinical end use. His research interests include designing of novel 68Ga/99mTc/188Re/177Lu-labeled molecules for varied diagnostic and therapeutic applications.
Boris Myasoedov is deputy secretary general for science of the Russian Academy of Sciences (RAS), head of laboratories at both the RAS Vernadsky Institute of Geochemistry and Analytical Chemistry and the RAS Frumkin Institute of Physical Chemistry and Electrochemistry. His scientific activity covers such fields as the fundamental chemistry of actinides, fuel reprocessing, partitioning of radioactive waste, and environmental protection. Myasoedov graduated from D.I. Mendeleev Chemical-Technology Institute in Moscow in 1954 and earned a Ph.D. in radiochemistry from the Vernadsky Institute in 1965 and his full doctorate in 1975 from the same institute. He was elected to the Russian Academy of Sciences in 1994 and has been awarded two State Prizes for his research on the chemistry of transplutonium elements (1986 and 2001), the Khlopin Prize for his studies of the chemistry of protactinium (1974), and the Ipatiev Prize of the RAS Presidium in 2003.
Evgeniy Nesterov is a research scientist in Laboratory No. 31 at the Nuclear Reactor, Institute of Physics and Technology, Tomsk Polytechnic University. He has 16 years of experience in research on and development on medical isotopes production and applications. Nesterov’s Ph.D. thesis was about production of Tc-99m generators. He has published more than 80 articles and is co-author of 8 patents.
Rodolfo Núñez-Miller is a board-certified nuclear medicine physician with more than 20 years’ experience in the field of nuclear medicine and molecular imaging. His background training was in internal medicine. Currently, he works as technical officer at the headquarters of the International Atomic Energy Agency in Vienna, Austria.
Joao Osso, from Brazil, holds the degrees of Ph.D. in nuclear chemistry from the University of Manchester, England, M.Sc. in nuclear engineering from the Federal University of Rio de Janeiro (UFRJ), Brazil, and B.Sc in chemistry from the University of Sao Paulo (USP), Brazil. He had more than 34 years of experience in the field of radioisotope and radiopharmaceutical production in Brazil before joining the International Atomic Energy Agency (IAEA) in February 2014. He is currently the head of the Radioisotope Products and Radiation Technology Section of the Division of Physical and Chemical Sciences at the IAEA in Vienna, Austria.
Ul-Jae Park works for the RI Research Division at the Korea Atomic Energy Research Institute (KAERI).
David Pellicciarini is vice president, Pharmacy Safety, Practice, and Technical Operations for Cardinal Health Nuclear Pharmacy Services (NPS). NPS operates 130 nuclear pharmacies, 30 positron emission tomography (PET) drug manufacturing facilities, and other radioactive drug manufacturing facilities. Pellicciarini has 25 years of experience in the radiopharmaceutical industry, including nuclear pharmacy, SPECT drug manufacturing, and PET
drug manufacturing. He holds a B.S. in physics from the University of Nevada, Reno, and an M.B.A. from the University of California at Los Angeles. He is a certified health physicist (by the American Board of Health Physics).
Eugene Peterson is executive advisor to Los Alamos National Laboratory’s associate director for chemistry, life, and earth sciences and is leading the laboratory’s strategic planning efforts for the Science of Signatures Science Pillar. Previously, he was the chemistry division leader at Los Alamos, where he was responsible for 350 chemical professionals and a budget of approximately $150 million. Before his tenure as chemistry division leader, Peterson specialized in medical isotope production and applications research and development. Peterson served on the National Academies Committee on Medical Isotope Production Without Highly Enriched Uranium (2007-2009) and the Committee on the State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium (2014-2016). He received his B.S. from the Illinois Benedictine College and his Ph.D. in inorganic chemistry from Arizona State University.
Katrina Pitas is vice president, Business Development, of SHINE Medical Technologies, Inc. Before joining SHINE in 2011, Pitas did research and development work for Phoenix Nuclear Labs. In her capacity as vice president of Business Development, she has played a key leadership role in implementing SHINE’s strategic vision and driving SHINE’s growth and development. Pitas was a key player in securing early funding for SHINE, and has also made important contributions to SHINE’s regulatory efforts. Pitas received her undergraduate degree in physics from Carleton College, and before joining Phoenix Nuclear Labs, she gained experience living in both China and Japan.
Bernard Ponsard has a master’s degree in physics (1983) and a master of science degree in nuclear energy (1985) from the Université Catholique de Louvain, Belgium. He joined the Belgian Nuclear Research Centre (SCK•CEN) in Mol in 1985 as a reactor physicist at the BR2 high-flux material testing reactor. He is currently head of the Radioisotopes and Silicon Production Unit at the BR2 reactor and is in charge of the strategic development of new medical radioisotopes for nuclear medicine, new radioisotopes for industrial applications, and new products for the semiconductor industry within SCK’s Institute for Nuclear Materials Science (NMS). He was chairman of the AIPES Reactors & Isotopes Working Group from 2010 until 2017 for securing the global supply of medical radioisotopes as Mo-99/Tc-99m. He is currently co-chair of the AIPES Security of Supply Working Group, chair of the Emergency Response Team, and chair of the European Observatory Working Group for the European Supply of Medical Radioisotopes—Global Reactor Scheduling and Mo-99 Supply Monitoring.
Yuri Shiyan is the director of the Russian Academy of Sciences (RAS) Committee on International Security and Arms Control and the head of the Office for Coordination of International Scientific Programs and Projects. He has worked in this capacity for more than 25 years, facilitating collaborative efforts and exchanges between international partners and Soviet/Russian scientists, engineers, and medical professionals. From 2004 through 2005, he served as an expert to the International Atomic Energy Agency Nuclear Fuel Subcommittee. For the past several years, he has served as coordinator of the RAS and National Academy of Sciences committees on counterterrorism and nonproliferation. Further, he has assisted several joint U.S.-Russian projects focusing on various aspects of the nuclear fuel cycle, including the storage of spent nuclear fuel.
Viktor Skuridin is the head of Laboratory No. 31 at the Nuclear Reactor, Institute of Physics and Technology, Tomsk Polytechnic University (TPU). He has 50 years of experience in medical isotopes production and applications research and development. He is leader of a research group in nuclear medicine at TPU. He is co-author of more than 150 articles and 30 patents. He is an Honored Worker of Science and Technics of the Russian Federation and holder of various other prizes.
Katherine (Kath) Smith is currently the counsellor nuclear at the Australian Embassy and Permanent Mission to the United Nations in Vienna. In this role, she develops briefs that underpin policy; participates in the Australian delegations to meetings convened by the United Nations; and manages relationships and facilitates interactions
and dealings between Australian Departments and Agencies and the International Atomic Energy Agency (IAEA), the OCED Nuclear Energy Agency (in Paris), and other nations/agencies. She also contributes to research related to nuclear waste forms and related materials. This role is fully funded by the Australian Nuclear Science and Technology Organisation (ANSTO).
Riane Stene graduated from the University of Texas at El Paso with a bachelor’s degree in chemistry. She then moved to the Pacific Northwest to pursue a master’s degree in radiochemistry from Washington State University. Currently, she is working on her Ph.D. as a joint student between the Technical University of Munich and Philipps University Marburg. Her Ph.D. research focuses on the dry chemical separation of molybdenum from uranium. After she earns her Ph.D., she would like to continue working in the field of molybdenum-99 production for medical use.
Bertrand Stepnik is working at AREVA. He is head of the CERCA research and development department. He has an engineering degree and a Ph.D. in physics. He is AREVA’s expert in uranium metallurgy.
Jean-Michel Vanderhofstadt serves as the chief executive officer of L’Institut National des Radioéléments (IRE); general manager of its subsidiary IRE-Environment and Lifescience Technology (IRE-ELiT SA), specializing in the production of medical radioisotopes for nuclear medicine; and president of TransRad, an IRE subsidiary company specializing in the transport of radioactive and nuclear material. Vanderhofstad also currently serves as the vice president and treasurer of the Association of Imaging Producers and Equipment Suppliers, which represents many of the major pharmaceutical and imaging equipment companies in the field of nuclear medicine in Europe; is the board director of BioWin, a local government-funded organization drawing together stakeholders (companies, research centers, and universities) involved in innovative research and development projects and/or skills development in the field of health biotechnology and medical technologies; and is an associate professor at the University of Liège, Belgium. Vanderhofstadt graduated from the University of Liège where he obtained a degree of industrial pharmacist and from the Free University of Brussels where he earned a post-degree in business management.
Jan Willem Velthuijsen is chief economist at PwC (PricewaterhouseCoopers) Europe. At PwC, he is responsible for the Competition & Regulation team, which supports companies, governments, and regulators on questions about market definition, competition, market entry, liberalization of markets, privatization, and state aid. He has worked in numerous industries, such as energy, financials, telecoms, transport and logistics, and healthcare. For 3 years, he has been responsible for the Thoughtleadership Programme of PwC Europe. He holds a chair in economics at the University of Groningen and is a visiting professor at the University of Oklahoma.
Meera Venkatesh is director of the Division of Physical and Chemical Sciences in the Department of Nuclear Applications at the International Atomic Energy Agency (IAEA). She is responsible for programs on radioisotope production and applications, radiation technology, and nuclear sciences. Before joining the IAEA in 2011, she worked for 34 years at the Indian Department of Atomic Energy, beginning as a young researcher in the area of radioisotopes and radiopharmaceuticals and growing to lead the Radioisotope and Radiopharmaceuticals Program for which she received awards of excellence from the Indian Nuclear Society and the Department of Atomic Energy, India. She has authored more than 200 papers in international journals and several book chapters and is an editor of two international journals. She has guided 12 Ph.D. students in areas of her expertise and is passionate about promoting peaceful applications of nuclear technologies.
Wolfgang Weber is a nuclear medicine physician with expertise in molecular imaging and targeted radionuclide therapy—particularly in the use of positron emission tomography in oncology. In addition to his role as chief of the Molecular Imaging and Therapy Service, he also serves as director of the Laurent and Alberta Gerschel Positron Emission Tomography Center at Memorial Sloan Kettering.
Christophe Xerri has 25 years of experience in nuclear fuel cycle and waste management. Before his appointment
to the International Atomic Energy Agency, he served from 2011 to 2015 as counsellor for Nuclear Affairs to the French Embassy in Japan and in Mongolia. He joined COGEMA (now AREVA) in 1991, in the field of spent fuel and waste management. He then moved to uranium mining and enrichment technology. Later, he worked in nonproliferation and international relations, and then was assigned to the office of the president of AREVA. He moved to Japan in 2007 and became vice president of Mitsubishi Nuclear Fuel in 2009, where he was also involved in handling the consequences of the earthquake and tsunami of March 2011.
Sergey Yudintsev is head of the Laboratory of Radiogeology and Radiogeoecology at the Institute of Geology of Ore Deposits, Petrography, Mineralogy, and Geochemistry of the Russian Academy of Sciences (IGEM RAS). He is a specialist in the field of management of radioactive waste derived in the closed nuclear fuel cycle. He graduated from Moscow State University (1981, geochemistry) and received his Ph.D. (1989) and Dr.Sc. (2009) degrees from the IGEM RAS. He was elected as a corresponding member of the RAS in 2011. He is now involved in research on geochemical-mineralogical aspects of safe radioactive waste disposal, including searching for new matrices for isolation of long-lived actinides and fission products. Dr. Yudintsev has published more than 250 papers in Russian and international journals and presented these results at a number of international conferences. He participated in the meetings of the Russian and American experts (Global Nuclear Energy Partnership and Advanced Fuel Cycle Initiative workshops).
Boris L. Zhuikov is head of the Laboratory of Radioisotope Complex of the Institute for Nuclear Research (INR) of the Russian Academy of Sciences in Moscow. He is responsible for the radioisotope investigation and production program at INR, including medical isotope investigation and production. He has been the project leader on a number of successful mutual U.S.-Russian Global Initiatives for Proliferation Prevention (GIPP) projects for development of medical isotope production. Zhuikov has been at INR since 1987. Prior to his employment at INR he was a research scientist at the Joint Institute for Nuclear Research, an international research center for nuclear sciences located at Dubna, Moscow Oblast. Zhuikov is author and co-author of more than 200 scientific and popular science publications including a review of medical isotope production in Russia. He is a member of the Scientific Council of the Institute for Nuclear Research of the Russian Academy of Sciences, the Russian Society of Nuclear Medicine, the American Nuclear Society, and the International Society of Nuclear Chemistry. He holds a B.Sc. in chemistry and a Ph.D. in radiochemistry from Moscow State University.
STAFF
Ourania (Rania) Kosti joined the staff of the Nuclear and Radiation Studies Board (NRSB) of the National Academies of Sciences, Engineering, and Medicine in January 2011. Prior to her current appointment, she was a postdoctoral fellow at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington, D.C., where she conducted research on biomarker development for early cancer detection using case-control epidemiologic study designs. She focused primarily on prostate, breast, and liver cancers and identification of those individuals who are at high risk of developing malignancies. Kosti also trained at the National Cancer Institute (2005-2007). She received a B.Sc. in biochemistry from the University of Surrey, UK, an M.Sc. in molecular medicine from University College London, and a Ph.D. in molecular endocrinology from St. Bartholomew’s Hospital in London, UK. Kosti’s interests within the NRSB focus on radiation health effects.
Rita Guenther, senior program officer for the National Academy of Sciences’ Committee on International Security and Arms Control (CISAC), is the responsible staff officer for this project. Recipient of a Fulbright-Hays Doctoral Dissertation Research Fellowship, Guenther manages CISAC’s Russia Dialogue. She has worked on or led several cooperative U.S.-Russian and Indo-U.S. projects, including a joint U.S.-Russian workshop on the future of the nuclear security environment in 2015; a study on indigenization of Russian nuclear material protection, control, and accounting programs; and Indo-U.S. workshops on science and technology for nuclear material security and on science and technology to counter terrorism. The Office of Science and Technology Policy and the Office of the Science and Technology Advisor to the Secretary of State has consulted her concerning reforms in Russian science.
Guenther received the National Academies distinguished service award in 2007. She speaks Russian fluently and holds an M.A. in Russian studies and a Ph.D. in history from Georgetown University.
Frances Marshall has been the project manager for the Research Reactor Fuel Cycle project in the Research Reactor Section at the International Atomic Energy Agency (IAEA), responsible for supporting Member States with research reactor fuel cycle issues since 2014. Prior to joining IAEA, she was manager of the Advanced Test Reactor (ATR) National Scientific User Facility (NSUF) Program at Idaho National Laboratory (INL) in the United States. She co-led the team to establish the ATR NSUF. At INL, Marshall supported and led projects in the areas of irradiation experiments, nuclear power plant engineering, nuclear power plant probabilistic risk analysis, and regulatory assessment. Marshall earned a bachelor’s degree in nuclear engineering from the University of Virginia (UVA) and a master’s degree in chemical engineering from the University of Idaho, and is a registered professional engineer. She held a reactor operator license on the UVA Reactor and worked in the commercial nuclear power industry as a startup engineer, plant systems engineer, and reactor engineer for 9 years prior to working at INL.
Tom Hanlon is a nuclear engineer in the Research Reactor Section at the International Atomic Energy Agency, responsible for project activities related to the low-enriched uranium conversions of Miniature Neutron Source Reactors (MNSRs) and production of Mo-99 without the use of highly enriched uranium. Prior to joining the IAEA, Hanlon served as a technical advisor to the National Nuclear Security Administration’s (NNSA’s) Mo-99 Program. He has also served as a project and program manager at the Y-12 National Security Complex and as an accelerator specialist at the Oak Ridge National Laboratory’s Spallation Neutron Source. Hanlon holds a master of business administration degree from the College of William and Mary, a master of science degree in applied physics from the University of Tennessee, and bachelor of arts degrees in both physics and music from Ripon College.
This page intentionally left blank.
